Loading…
Sectoral / Thematic · UTI Mutual Fund · AMFI code 100806UTI - Healthcare Fund
Disclosed for 95 months, Jul 2017 to Sep 2026.
Portfolio value
₹354 Cr
up ₹21.8 Cr vs Sep 2017
- Stocks held
- 25
- unchanged
- Top 10 weight
- 60.4%
- of the portfolio in its ten largest
- Cash & debt
- 1.5%
- cash, money market and debt
- Moves this month
- 0 in · 0 out
- added to 10, trimmed 3
UTI - Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In October 2017 it disclosed 25 stocks worth ₹354 Cr, up ₹21.8 Cr from Sep 2017. Its largest positions were Dr. Reddy's Laboratories Limited (9.5%), Aurobindo Pharma Limited (8.4%), Cipla Limited (7.2%); the ten largest together made up 60.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 71.7% of its equity. Cash and debt stood at 1.5%. Compared with Sep 2017 the fund entered 0 new stocks and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
84%
Top-10 weight is higher than 84% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
21%
Holds more cash than 21% of peers
What these mean: concentration · cash
Holdings in October 2017
Download CSVEvery line the fund disclosed, with the change against Sep 2017. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Dr. Reddy's Laboratories Limited | 9.45% | down 0.21 pts | ₹33.5 Cr | up ₹1.4 Cr | Added |
| Aurobindo Pharma Limited | 8.40% | up 0.25 pts | ₹29.8 Cr | up ₹2.7 Cr | Added |
| Cipla Limited | 7.19% | up 1.57 pts | ₹25.5 Cr | up ₹6.8 Cr | Added |
| Sun Pharmaceutical Industries Limited | 7.00% | down 0.44 pts | ₹24.8 Cr | up ₹6 L | Held |
| Strides Pharma Science Limited | 6.20% | up 0.68 pts | ₹22 Cr | up ₹3.6 Cr | Added |
| Torrent Pharmaceuticals Limited | 5.81% | up 0.43 pts | ₹20.6 Cr | up ₹2.7 Cr | Added |
| Alkem Laboratories Limited | 4.29% | up 0.17 pts | ₹15.2 Cr | up ₹1.5 Cr | Added |
| Natco Pharma Limited | 4.11% | up 0.55 pts | ₹14.6 Cr | up ₹2.7 Cr | Added |
| Piramal Enterprises Limited | 3.97% | down 0.07 pts | ₹14 Cr | up ₹64 L | Added |
| Dishman Carbogen Amcis Limited | 3.95% | down 0.83 pts | ₹14 Cr | down ₹1.9 Cr | Trimmed |
| Pfizer Limited | 3.93% | down 0.25 pts | ₹13.9 Cr | up ₹4 L | Held |
| Sanofi India Limited | 3.91% | up 0.12 pts | ₹13.9 Cr | up ₹1.3 Cr | Added |
| Zydus Lifesciences Limited | 3.17% | up 0.01 pts | ₹11.2 Cr | up ₹72 L | Added |
| Ajanta Pharma Limited | 3.07% | up 0.71 pts | ₹10.9 Cr | up ₹3 Cr | Added |
| Narayana Hrudayalaya Limited | 2.89% | down 0.15 pts | ₹10.2 Cr | up ₹13 L | Added |
| Sun Pharma Advanced Research Company Limited | 2.88% | up 0.10 pts | ₹10.2 Cr | up ₹96 L | Added |
| Max India Limited | 2.84% | down 0.27 pts | ₹10.1 Cr | down ₹28 L | Trimmed |
| FDC Limited | 2.83% | down 0.09 pts | ₹10 Cr | up ₹30 L | Added |
| IPCA Laboratories Limited | 2.56% | up 0.07 pts | ₹9.1 Cr | up ₹78 L | Added |
| Unichem Laboratories Limited | 2.23% | up 0.47 pts | ₹7.9 Cr | up ₹2.1 Cr | Added |
| Indoco Remedies Limited | 2.20% | up 0.75 pts | ₹7.8 Cr | up ₹3 Cr | Added |
| Apollo Hospitals Enterprise Limited | 1.88% | down 0.06 pts | ₹6.7 Cr | up ₹22 L | Added |
| Dr. Lal Path Labs Limited | 1.72% | down 0.17 pts | ₹6.1 Cr | down ₹20 L | Trimmed |
| Cash, TREPS & receivables | 1.50% | down 3.38 pts | ₹5.3 Cr | down ₹10.9 Cr | Trimmed |
| Divi's Laboratories Limited | 1.12% | down 0.04 pts | ₹4 Cr | up ₹12 L | Added |
| Shilpa Medicare Limited | 0.88% | up 0.07 pts | ₹3.1 Cr | up ₹42 L | Added |
What changed, Sep 2017 to Oct 2017
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Cipla Limitedup ₹6.8 Cr (+1.57% pts)
- Strides Pharma Science Limitedup ₹3.6 Cr (+0.68% pts)
- Ajanta Pharma Limitedup ₹3 Cr (+0.71% pts)
- Indoco Remedies Limitedup ₹3 Cr (+0.75% pts)
- Natco Pharma Limitedup ₹2.7 Cr (+0.55% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Sep 2017, the weight rose most in Pharmaceuticals & Biotechnology (+0.6 pts) and Pharmaceuticals (+0.6 pts), and fell most in Healthcare Services (−1.0 pts) and Finance (−0.2 pts).
- Pharmaceuticals & Biotechnology71.1% → 71.7%+0.6 pts
- Pharmaceuticals14.2% → 14.8%+0.6 pts
- Healthcare Services10.5% → 9.5%−1.0 pts
- Finance4.2% → 4.0%−0.2 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2017 | Sep 2017 | Oct 2017 |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 67.6% | 71.1% | 71.7% |
| Pharmaceuticals | 15.5% | 14.2% | 14.8% |
| Healthcare Services | 11.8% | 10.5% | 9.5% |
| Finance | 5.0% | 4.2% | 4.0% |
Allocation in Oct 2017change vs Sep 2017
- Pharmaceuticals & Biotechnology (16)71.7%▲ 0.6 pts
- Pharmaceuticals (4)14.8%▲ 0.6 pts
- Healthcare Services (4)9.5%▼ 1.0 pts
- Finance (1)4.0%▼ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Oct 2017
1.5%
▼ 3.4 pts vs Sep 2017
- Cash alone
- 1.5%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 1.5% – 7.3%
- lowest to highest · record 7.3% in Jul 2017
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.